



FOR IMMEDIATE RELEASE

September 19, 2019

Contact: Jacqueline Clark, jacqueline@sqcomms.com

Charlie Patterson, charlie@sqcomms.com

George Hodgin, CEO of Biopharmaceutical Research Company, praises Former FDA Commissioner's Call for Cannabis Research

MONTEREY, CA - September 19, 2019 - Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb has called for increased research into cannabis-derived treatments. Yesterday, the Senate Appropriations Committee issued a report in which it called on regulators to lower the regulatory burden on cannabis research.

George Hodgin, former Navy SEAL and founder and CEO of Biopharmaceutical Research Company (BRC), issued the following statement praising the former Commissioner's remarks and the Committee report:

"I am heartened to know that former FDA Commissioner Scott Gottlieb stands behind efforts to increase access to federally legal cannabis research. The BRC team thanks him for recognizing that the current government monopoly that has existed for over 60 years surrounding this research is insufficient to determine the medicinal promise of cannabis. He is correct that the body of evidence regarding cannabis is thin, and it will continue to be unless decisive action is taken to increase the study of these compounds.

"If we can eliminate federal barriers to research, patients across America stand to benefit from medicinal cannabis, including many of my fellow veterans who struggle with combat-related ailments. The Drug Enforcement Administration (DEA) should move to review these research applications immediately, so companies like mine can get down to business in identifying treatments, uncovering risks and creating jobs and intellectual property right here in the United States.

"The Senate Appropriations Committee has also taken bold steps in outlining their concerns with the lack of available research and information, which is critical for increasing the availability of proven cannabis-derived treatments as well as determining public safety measures that need to be in place when it comes to regulating cannabis products. This call from the Committee should be taken seriously by regulators when it comes to removing barriers to research."

George Hodgkin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC's work, visit <https://www.biopharmaresearchco.com/>.

About Biopharmaceutical Research Company

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world. BRC also conducts federally compliant cannabis-specific analytical activities.

###